Clinigen Group Plc (CLIGF) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Clinigen Group Plc (NASDAQ:CLIGF) from a hold rating to a buy rating in a research report released on Tuesday. The brokerage currently has $15.00 target price on the stock.
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
Clinigen Group Plc (CLIGF) opened at 13.90 on Tuesday. Clinigen Group Plc has a one year low of $8.70 and a one year high of $13.90. The firm has a market capitalization of $1.60 billion and a price-to-earnings ratio of 86.34.
Receive News & Stock Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related stocks with our FREE daily email newsletter.